文献速递治疗药物监测与药物基因组学

皮下注射ravulizumab剂量优化可节省费用并提高患者便利性

Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness.
PubMed 文献 · Br J Clin Pharmacol · 2022-12-01

本研究基于制造商注册数据,在计算机模拟中探索皮下注射ravulizumab的替代剂量方案。将给药间隔从1周延长至2周或基于治疗药物监测的个体化给药,可获得治疗性ravulizumab浓度,乳酸脱氢酶正常化的预测疗效相当,剂量可减少高达64%。个体化剂量可大幅降低皮下ravulizumab剂量并提高患者便利性。

要点

  • 皮下ravulizumab标准方案在多数患者中产生超治疗浓度。
  • 间隔延长至2周或TDM个体化给药可维持治疗浓度。
  • 个体化剂量可减少高达64%且预测疗效相当。

核心结论

  • 皮下注射ravulizumab的个体化剂量可大幅降低剂量并提高患者便利性。

研究设计与样本

  • 基于制造商注册数据的计算机模拟(in silico)研究。

主要发现

  • 批准的皮下给药方案在注册研究中使多数患者ravulizumab浓度超治疗水平。
  • 将给药间隔从1周延长至2周或基于治疗药物监测的个体化给药,可获得治疗性ravulizumab浓度。
  • 上述方案的预测疗效在乳酸脱氢酶正常化方面相当,剂量减少高达64%。

临床怎么用

  • 可考虑将皮下ravulizumab给药间隔从1周延长至2周或基于治疗药物监测进行个体化剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ravulizumab is an expensive complement C5-inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria. Recently, a subcutaneous formulation has entered the market, for which the approved dosing regimen results in supratherapeutic ravulizumab concentrations in the majority of patients in the registration studies. Therefore, we explored alternative dosing regimens in silico based on the registration data of the manufacturer. Extending the interval from 1 to 2 weeks or individualized dosing based on therapeutic drug monitoring resulted in therapeutic ravulizumab concentrations and comparable predicted efficacy in terms of lactate dehydrogenase normalization, with dose reductions up to 64%. We here show that with an individualized dose, a substantial dose reduction for subcutaneous ravulizumab might be possible with improved patient-friendliness.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ter Avest M, Langemeijer SMC, Blijlevens NMA, et al. Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness. Br J Clin Pharmacol. 2022. PMID: 36394176. doi:10.1111/bcp.15602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。